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Abstract 25 
ARHGAP25 is a Rac-specific GTPase activating protein that is expressed primarily in 26 
hematopoietic cells. The involvement of ARHGAP25 in regulating the recruitment of 27 
leukocytes to inflammatory sites was investigated in genetically modified mice. Using 28 
intravital microscopy we show that Arhgap25-deficiency affects all steps of leukocyte 29 
recruitment with a predominant enhancement of transendothelial migration of neutrophilic 30 
granulocytes. Increased transmigration of Arhgap25-deficient leukocytes is demonst ated in 31 
inflamed cremaster muscle venules, in a peritonitis model, and in an in vitro chemotaxis 32 
assay. Using bone marrow chimeric mice lacking ARHGAP25 in the hematopoietic 33 
compartment, we show that enhanced migration in the absence of ARHGAP25 is due to 34 
defective leukocyte function. In search for potential mechanisms of ARHGAP25-regulated 35 
migration of neutrophils, we detected an increase in the amount of active, GTP-bound Rac 36 
and Rac-dependent cytoskeletal changes in the absence of ARHGAP25 suggesting a critical 37 
role of ARHGAP25 in counterbalancing the Rac-activating effect of nucleotide exchange 38 
factors. Taken together, using Arhgap25-deficient mice we identified ARHGAP25 as a 39 
relevant negative regulator of leukocyte transendothelial migration.   40 
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Introduction 41 
In inflammation, neutrophil recruitment to sites of injury is essential for the fast and effective 42 
elimination of injurious agents. The first step of recruitment consists in the activation of 43 
vascular endothelial cells, which leads to increased expression of several cell surface 44 
molecules including selectins and integrin ligands (1, 2). These molecules are recognized by 45 
circulating leukocytes enabling the stepwise recruitment and extravasation of leukocytes into 46 
inflamed tissue. Capture to the inflamed endothelium is followed by rolling of leukocytes 47 
along the endothelium. Both capture and rolling are mediated by endothelial selectins and 48 
leukocyte expressed selectin ligands (3). During rolling, leukocytes get into intimate contact 49 
with the endothelial surface which enables binding of endothelium-expressed chemokines to 50 
their respective ligand on the leukocyte surface triggering firm arrest of leukocyte on the 51 
endothelium.  Thereafter, leukocytes begin to crawl along the vessel wall searching for an 52 
appropriate exit point for transmigration into tissue (diapedesis) (2, 4, 5). Extravasated 53 
leukocytes are directed by chemotactic agents to the pathogens to be eliminated (6). All these 54 
different types of movements require a precise spatial and temporal organization of the actin 55 
cytoskeleton (7-9). Although our knowledge on the involved receptors and signaling 56 
pathways has increased tremendously in the last decade (10), differences in the molecular 57 
organization of the actin cytoskeleton underlying the different types of movements are still 58 
poorly understood. 59 
Members of the Rac/Rho subfamily of small GTP-binding proteins are key regulators 60 
of the actin cytoskeleton (11). Their prevalence in the active, GTP-bound state depends on the 61 
balance between the three major regulatory proteins: guanine nucleotide exchange factors 62 
(GEFs) that promote the active state, GTPase activating proteins (GAPs) that counteract it, 63 
and guanine nucleotide dissociation inhibitors (GDI) that conserve the inactive state (12, 13). 64 
In case of the Rac/Rho subfamily, the potential number of GEFs and GAPs expressed in a 65 
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specific cell is especially high (14). The majority of these GEFs and GAPs are large proteins 66 
composed of several effector, interactive and regulatory domains that suggest multiple 67 
functions (13, 14). In neutrophils, a specific involvement of certain GEFs has been 68 
investigated for different neutrophil effector functions including chemotaxis and adhesion 69 
(15-17). In contrast, similar data on potentially interacting GAPs are still scarce (18-20). 70 
In a recent study, we have shown that ARHGAP25 is a Rac-specific GAP expressed 71 
primarily in hematopoietic cells (21). We also demonstrated that ARHGAP25 serves as a 72 
negative regulator of phagocytosis and related superoxide production (21, 22). The aim of the 73 
present study was to reveal the role of ARHGAP25 in the complex process of leukocyte 74 
recruitment during inflammation. We provide the first detailed description of the Arhgap25-/- 75 
mice, and show that loss of ARHGAP25 affects several steps along the recruitment cascade 76 
leading to a proinflammatory phenotype with elevated transmigration of neutrophils into 77 
inflamed tissue which is accompanied by increased Rac activity in neutrophils. 78 
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Materials and Methods 79 
Antibodies and reagents  80 
Anti-CD11b-PE and anti-Ly-6G-Pacific Blue were purchased from BioLegend, rat IgG2bκ-81 
PE isotype control and anti-CD18-FITC from BD Biosciences, rat IgG2a-APC isotype 82 
control, anti-CD11a-APC, anti-human Fcγ-biotin, Streptavidin-PECy5 and rat IgG2a-FITC 83 
isotype control from eBioscience, anti-CXCR2-APC, recombinant murine (rm) TNFα, rmE-84 
selectin/CD62E-Fc chimera and rmICAM-1/CD54-Fc chimera from R&D Systems, 85 
rmKC/CXCL-1 and rmCXCL12 from PreproTech, Ly-6G-PerCP-Cy5.5 and CD11b-PE from 86 
BD Pharmingen, mouse anti-Rac antibody from BD Transduction Laboratories, 87 
paraformaldehyde from Sigma-Aldrich. Anti-human ARHGAP25 polyclonal antibody was 88 
prepared as described previously.(21) Cross-reactivity with mouse ARHGAP25 was tested 89 
using the lysate of COS-7 cells transfected with human ARHGAP25-V5 and mouse Arhgap25-90 
V5 constructs (see Fig. S1 for details). All other reagents were of research grade. 91 
 92 
Mice 93 
The Arhgap25-/- mouse strain used for this research project was created from ES cell clone 94 
(EPD0085_1_C10) obtained from the NCRR-NIH supported KOMP Repository 95 
(www.komp.org) and generated by the CSD consortium for the NIH funded Knockout Mouse 96 
Project (KOMP). Methods used on the CSD targeted alleles have been published in (23). 97 
Arhgap25-/- mice had a C57BL/6 genetic background and were maintained in a homozygous 98 
breeding colony. Genotyping was performed according to KOMP’s instructions using the 99 
following primers: Common-loxP-F: 5’-GAGATGGCGCAACGCAATTAAT-3’; CSD-100 
Arhgap25-SR1: 5’- GCATGAGGCAGCTGTTCTTAGTTACC-3’; CSD-Arhgap25-GF4: 5’-101 
TGCACACGGTGGCATCTCTACTAAAG-3’. Analysis of blood parameters was carried out 102 
with a haemocytometer. To reveal differences in body weight between wild type and 103 
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Arhgap25-/- mice, 5-week-old animals (3 males/genotype and 2 females/genotype) were 104 
weighed for 14 weeks. Arhgap25-/- and control wild-type bone marrow chimeras were 105 
generated using bone marrow cells from adult donors as described previously (24, 25). 106 
Arhgap25-/- bone marrow cell suspensions were injected intravenously into lethally irradiated 107 
(11.5-Gy) recipients carrying the CD45.1 allele on the C57BL/6 genetic background. An 108 
equal number of control chimeras were also generated using Arhgap25-expressing 109 
(Arhgap25+/+) bone marrow cells and will be referred to as wild-type chimeras. Efficiency of 110 
repopulation of the hematopoietic compartment by donor-derived cells was more than 98%, 111 
tested 4 weeks after transplantation by flow cytometry: we tested the expression of CD45.2 112 
(donor) allele in the granulocyte gate determined by Ly-6G-staining, as described previously 113 
(24, 25) (data not shown). Bone marrow chimeras were used 4-8 weeks after transplantation. 114 
Mouse strain carrying the CD45.1 allele on the C57BL/6 genetic background (B6.SJL-Ptprca) 115 
was purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were kept in 116 
individually sterile ventilated cages (Tecniplast, Buguggiate, Italy) in a conventional facility. 117 
Age and gender-matched animals were used for all the experiments. Animal experiments were 118 
approved by the Regierung von Oberbayern, Germany, AZ 55.2.1.54-2532-76-12, and by the 119 
Governmental Office of Pest County, Hungary (22.1/S321/3/2011). 120 
 121 
Intravital microscopy of the mouse cremaster muscle 122 
Mice were pretreated with intrascrotal injection of 500 ng rmTNFα per mice. After 2 h, mice 123 
were anesthetized and trachea and carotid artery were cannulated. Scrotum was opened, the 124 
cremaster muscle exteriorized, spread over a cover glass and superfused with 35 °C 125 
bicarbonate-buffered saline as described (26). Parameters of rolling, adhesion and crawling 126 
were determined using an Olympus BX51WI intravital microscope equipped with a saline 127 
immersion objective (40/0.8 NA, Olympus) and a CCD camera (model CF8/1, Kappa). All 128 
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scenes were recorded by the Virtual Dub software for later offline analysis. Systemic blood 129 
samples (~ 50 µL) were collected through the carotid artery catheter before and during the 130 
experiment and analysed using a haemocytometer. The offline analysis of venular diameter 131 
and vessel segment length of postcapillary venules (between 20-40 µm in diameter) was 132 
carried out with Fiji software (27). Leukocyte rolling flux fraction was calculated from the 133 
number of rolling cells that crossed a perpendicular line through a given vessel within 1 min 134 
in relation to the total number of circulating leukocytes (28). Velocities of rolling and 135 
crawling were measured using MTrackJ plugin of Fiji software. Other experimental 136 
parameters (centerline blood flow velocity, shear rate, systemic cell counts) are shown in 137 
Table SI. 138 
 139 
TNFα-induced peritonitis model 140 
Mice were treated with intraperitoneal injection of 5 µg rmTNFα in a final volume of 100 µL. 141 
Three hours after treatment, mice were sacrificed and peritoneal cavity was washed with 5 mL 142 
ice-cold PBS supplemented with 20 mM HEPES and 10 mM EDTA. Ly-6G+ infiltrated cells 143 
were analysed with BD FACSCalibur device. Cell counts were determined using Flow-Count 144 
Fluorospheres (Beckman Coulter).   145 
 146 
Histology 147 
Three hours after intrascrotal injection of rmTNFα (500 ng in 200 µL/mouse) or sterile PBS 148 
(200 µL/mouse), cremaster muscles were exteriorized, mounted on adhesive slides 149 
(Superfrost, Thermo Scientific) and fixed in 4% (w/v) paraformaldehyde for at least 48 h at 150 
4°C. Then samples were washed 3x5 min in 0.1 M Phosphate buffer (0.1 M NaH2PO4, 0.1 M 151 
Na2HPO4 mixed in 81:19 ratio, pH 7.4) supplemented with 5% (v/v) ethanol and stained with 152 
Giemsa’s azure eosin methylene blue solution (Merck) for 4 min. After a rinse with water, 153 
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slices were differentiated with 0.03% (v/v) acetic acid for 10 min, and immersed in ascending 154 
alcohol series from 70% (v/v) to absolute alcohol, in each for 3 min. Draining was carried out 155 
with xylol (2x5 min), followed by sealing with rectangular coverslips using Eukitt (Sigma-156 
Aldrich). Whole mounts were analyzed with a Zeiss microscope equipped with an oil 157 
immersion objective (100x/1.4 NA, Zeiss). Whole mounts of bone marrow chimeras were 158 
analyzed with a Leica DMI 6000 B microscope equipped with an oil immersion objective 159 
(63x/1.25 NA, Leica).  160 
After 3 hours of TNFα challenge peritoneal tissue samples were taken and fixed in 4% 161 
(w/v) phosphate-buffered paraformaldehyde for 48 hours. The tissue samples were paraffin-162 
processed, embedded, and 4 µm sections cut with a Microm HM340E rotary microtome 163 
(Thermo Fisher Scientific). Cut sections were then used for hematoxylin and eosin (H&E) 164 
staining. Representative pictures were captured with a Nikon ECLIPSE Ni microscope 165 
equipped with 10x/0.30 NA and 40x/0.75 NA dry objectives (Nikon) and a Nikon DS-Ri2 166 
camera. Images were processed with NIS Elements v4.50 Imaging Software (Nikon). 167 
 168 
Ex vivo flow chamber assay 169 
Glass capillaries (Rectangular Boro Capillaries, 0.04x0.40mm, VitroCom) were coated 170 
overnight with rmE-selectin (CD62E Fc chimera, 20 µg/mL) or a combination of rmE-171 
selectin and rmICAM-1 (ICAM-1 Fc chimera, 15 µg/mL) or a combination of  rmE-selectin 172 
and rmICAM-1 and rmKC/CXCL-1 (15 µg/mL) at 4°C followed by blocking with 5% (w/v) 173 
casein (Sigma-Aldrich) in PBS for 2h. Carotid artery catheter was connected directly to one 174 
end of the chamber; while the other end was left open to regulate blood flow (shear stress 175 
level was at 3-4 dyn/cm2). One representative field was recorded for 5 min using an Olympus 176 
BX51WI intravital microscope equipped with a water immersion objective (40/0.8 NA, 177 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
9 
 
Olympus) and a CCD camera (model CF8/1, Kappa). Rolling velocity was determined using 178 
MTrackJ plugin of Fiji software. 179 
 180 
Transwell migration assay 181 
In vitro migration of neutrophils was tested using a Transwell (Corning) assay with inserts of 182 
3 µm pore size coated with 10% fetal bovine serum (FBS) for 1 hour at 37°C. Isolated cells 183 
were pretreated with 50 µg/mL TNFα for 10 min in a 37°C incubator humidified with 5% 184 
CO2. For chemoattractant, 50ng/mL CXCL12 was used per well, containing 1x106 cells. After 185 
1 hour incubation at 37°C, transmigrated cells were counted using an acid phosphatase assay 186 
(29). 187 
 188 
Determination of leukocyte adhesion proteins and filamentous actin 189 
Neutrophils were isolated from bone marrow with percoll gradient centrifugation as described 190 
previously (30). To determine cell surface expression of several receptors involved in 191 
neutrophil migration, 100 µL whole blood was obtained retro-orbitally from wild type and 192 
knock out mice pretreated with 500 ng TNFα intrascrotally for 2 h. Alternatively, 193 
transmigrated cells were collected from the Transwell plate.  Then, whole blood or 194 
transmigrated neutrophil samples were transferred into 5 mL centrifuge tubes. Samples were 195 
washed once with 3 mL HBSS+ medium (Hank’s Balanced Salt Solution (Sigma-Aldrich) 196 
supplemented with 1 mM CaCl2, 1 mM MgCl2, 0.1% (w/v) glucose, 10 mM HEPES and 197 
0.25% (w/v) Bovine Serum Albumin (BSA), pH 7.4) and centrifuged with 350g for 5 min at 198 
RT. Cells were stained with the indicated antibodies diluted in FACS buffer (PBS containing 199 
1% (w/v) BSA), for 20 min at 4°C. After staining, 1 mL FACS Lysing Solution (BD 200 
BioSciences) was added to the samples and cells were fixed on ice for 10 min. Then cells 201 
were centrifuged with 350 g for 5 min at RT, resuspended in 300 μL FACS buffer and 202 
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analyzed by flow cytometry (Beckman Coulter Gallios). For actin-staining, 1x106 bone 203 
marrow derived neutrophils were fixed with 4% (w/v) paraformaldehyde for 20 min at RT 204 
and centrifuged with 500 g for 5 min at RT. Cells were permeabilized with 0.1% (v/v) Triton-205 
X-100 for 5 min at RT, then stained with Alexa-488-phalloidin (Life Technologies) in 1:500 206 
dilution for 20 min at RT. Filamentous actin amount was analyzed with BD FACSCalibur 207 
device. To investigate actin-polymerization in time, 1x106 bone marrow derived neutrophils 208 
were stimulated with 50 ng/mL TNFα from 0 to 15 min at 37 °C. After stimulation, cells were 209 
fixed and labelled with Alexa-488-phalloidin as detailed above. 210 
 211 
Soluble ICAM-1 binding assay 212 
For each sample, 1.5x106 cells were resuspended in 30 μl HBSS+ and prewarmed at 37°C for 213 
1 min. Pre-complexed master mix containing rmICAM-1-human Fc in 20 μg/mL, anti-human 214 
IgG1-biotin in 10 μg/mL, Streptavidin-PE-Cy5 in 1:100 dilution and the indicated stimulus 215 
were also prewarmed for 10 min at 37°C. Then, 10 μL pre-complexed master mix was added 216 
to 30 μL cell suspension and incubated f r 3 min at 37°C. Reaction was stopped with 900 μL 217 
ice-cold FACS Lysing Solution, samples were transferred on ice and fixed for 10 min. Cells 218 
were washed with 2 mL HBSS+ and centrifuged with 350 g for 5 min at 4 °C. Then cells were 219 
stained with anti-Ly-6G-Pacific Blue in 1:600 dilutions for 20 min at 4°C. After a washing 220 
step (350 g, 5 min at 4°C in 2 mL HBSS+), cells were resuspended in 300 μL HBSS+ and 221 
analyzed by flow cytometry (Beckman CoulterGallios). 222 
 223 
Measurement of the amount of active Rac 224 
The cellular levels of GTP loaded Rac were determined with pull-down assay using GST 225 
fusion proteins containing the GTPase-binding domain of p21-activated kinase (PAK) (GST-226 
PBD) as described (31, 32). GST-PBD has been expressed in Escherichia coli. For pull-down, 227 
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bone marrow-derived neutrophils were activated with 50 ng/mL TNFα in HBSS+ medium at 228 
37 °C for 10 min. Basal Rac-activation was determined from resting cells. Whole cell lysates 229 
were run on SDS-PAGE, blotted onto nitrocellulose (33) and stained with anti-Rac antibody 230 
in 1:5000 dilution. Bound antibody was detected with enhanced chemiluminescence using 231 
horseradish peroxidase-conjugated anti–mouse-Ig (from sheep) secondary antibody (GE 232 
Healthcare) used in 1:5000 dilution. ImageJ software was used for densitometry analysis. 233 
 234 
Statistical analysis  235 
All data were analyzed and plotted using SigmaPlot 11.0 Software (Systat Software, Inc.). 236 
Pairwise comparison of experimental groups was carried out with paired t-test or Mann-237 
Whitney Rank Sum Test or two way ANOVA followed by a Tukey post-hock test, depending 238 
on the condition. All P-values<.05 were considered statistically significant.  239 
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Results 240 
 241 
Arhgap25 knockout mice 242 
Arhgap25 knockout mice were generated by the CSD consortium for the NIH funded 243 
Knockout Mouse Project (KOMP) inserting the L1L2_Bact_P cassette upstream of the 6th 244 
exon of the Arhgap25 gene. The cassette contains the following sites and sequences in the 245 
given order: FRT, lacZ, loxP, neomycin (under the control of the human beta-actin promoter), 246 
SV40 polyA, FRT, loxP. A third loxP site was inserted downstream of the 6th exon (23). 247 
Fertile homozygous mice (Arhgap25-/-) were obtained with the expected Mendelian ratios 248 
(data not shown) and did not show any obvious phenotype. No ARHGAP25 protein could be 249 
detected in either bone marrow derived neutrophils or in the spleen of Arhgap25-/- mice (Fig. 250 
S1A, B). Blood panel (e.g. circulating cell counts, hematocrit, mean corpuscular hemoglobin, 251 
mean corpuscular hemoglobin concentration) of Arhgap25-/- mice did not differ from the wild 252 
type (Arhgap25+/+) (Table I, Table SII). We assessed the body weight of male and female 253 
mice during a 130 days period and in 3 independent experiments. Body weight of male 254 
Arhgap25-/- mice was decreased c mpared to wild type but in the case of female mice, no 255 
difference was observed (Fig. S2). 256 
 257 
Reduced leukocyte rolling velocity and prolonged crawling in the absence of 258 
ARHGAP25 259 
Using intravital microscopy, we first investigated leukocyte rolling, adhesion and crawling in 260 
TNFα-stimulated cremaster muscle venules of WT (Arhgap25+/+) and Arhgap25-/- mice in 261 
vivo. Microvessel diameters, wall shear rates, centerline blood flow velocities and circulating 262 
leukocyte counts were similar between wild type and Arhgap25-/- mice (Table SI). While we 263 
observed no difference in leukocyte rolling (Fig. 1A), mean leukocyte rolling velocity was 264 
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markedly decreased in the absence of ARHGAP25 (Fig. 1B). Furthermore, we analyzed the 265 
number of adherent leukocytes and found no difference in adhesion between Arhgap25-/- and 266 
WT mice (Fig. 1C). Next, we investigated leukocyte crawling along the inflamed 267 
endothelium. Individual crawling paths of >140 cells were analyzed per group (Fig. 1D and 268 
E). We did not observe any difference in crawling directionality or accumulated distance 269 
between WT and ARHGAP25-/-mice (Fig. 1D-F). However, we found a significant increase in 270 
crawling velocity and Euclidean distance in Arhgap25-/- mice compared to WT mice (Fig. 1G 271 
and H) suggesting that ARHGAP25 is regulating leukocyte crawling in vivo. 272 
 273 
Lack of ARHGAP25 augments transendothelial migration in vivo. 274 
Next, we studied leukocyte extravasation in TNFα-stimulated cremaster muscle whole mount 275 
preparations of WT and Arhgap25-/- mice. As shown in Fig. 2A-B, Arhgap25+/+ leukocytes 276 
were found mainly in the vessels and the extravasated cells were scattered in the tissue. In 277 
contrast, a large number of Arhgap25-/- leukocytes lined up around the vessel from which they 278 
extravasated (Fig. 2C-D). Transendothelial migration was quantified and we found a 279 
significant increase in leukocyte extravasation in Arhgap25-/- compared to WT mice (Fig. 2E). 280 
Intrascrotal injection of PBS as a control caused no significant difference between WT and 281 
Arhgap25-/- mice (P= 0.194, data not shown). Further analysis of the different leukocyte 282 
populations extravasated into the inflamed cremaster muscle tissue revealed that the major 283 
component of extravasated leukocytes were neutrophilic granulocytes (PMN), followed by 284 
monocytes and lymphocytes (marked as “Others”) and eosinophils (Fig. 2F). Increased 285 
leukocyte extravasation upon TNFα stimulus was confirmed in an acute peritonitis model. 286 
Analyzing the H&E stained sections of inflamed peritoneal tissue, elevated leukocyte 287 
infiltration was observed in Arhgap25-/- mice compared to WT (Fig. 3A). Specific analysis of 288 
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Ly-6G+ neutrophil count in peritoneal lavage revealed a significant increase in case of 289 
Arhgap25-/- neutrophils compared to WT (Fig. 3B).  290 
 291 
Leukocyte rolling and adhesion under ex vivo conditions and in vitro Transwell 292 
migration assay.  293 
As Arhgap25-/- mice are complete knockout mice, the question arose, whether the observed 294 
alterations are due to functional changes in leukocytes or endothelial cells. To investigate the 295 
contribution of leukocytes on the recruitment phenotype observed in Arhgap25-/- mice, we 296 
performed ex vivo flow chamber assays and assessed rolling and adhesion of leukocytes in 297 
flow chambers coated with adhesion relevant proteins. In flow chambers coated with 298 
recombinant murine (rm)E-selectin, we saw a 2.5-fold increase in the number of rolling 299 
Arhgap25-/- leukocytes compared to wild type leukocytes (Fig. 4A). Next, we analyzed 300 
leukocyte adhesion in flow chambers coated with rmE-selectin alone, with rmE-selectin and 301 
rmICAM-1, and with rmE-selectin, rmICAM-1 and rmCXCL-1. Similar to the in vivo results 302 
we found no difference in the number f adherent cells between the different groups (Fig. 303 
4B). However, when we analyzed leukocyte rolling velocities, lack of ARHGAP25 resulted in 304 
a significant decrease in rolling velocity (Fig. 4C) in flow chambers coated with rmE-selectin 305 
or with rmE-selectin and rmICAM-1 surface (Fig. 4C). 306 
Taken together, we were able to reproduce under ex vivo conditions the pattern of 307 
rolling and adherence observed in ARHGAP25-deficient animals under in vivo conditions 308 
suggesting that loss of ARHGAP25 in leukocytes accounts for the observed pro-inflammatory 309 
phenotype.  310 
In order to test the role of ARHGAP25 in cell migration under in vitro conditions, we 311 
determined neutrophil migration toward CXCL12 in a Transwell assay. As shown in Fig. 4D,  312 
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 Arhgap25-/- neutrophils pretreated with TNFα for 10 min showed a significant increase in 313 
transmigration compared to WT. 314 
 315 
Verification of altered leukocyte function in bone marrow chimeras 316 
In view of the decisive role of the adhesive surface provided in vivo by the endothelial cells 317 
we wanted to verify our flow chamber data in bone marrow chimeric mice. These animals 318 
express the CD45.1 allele and carry Arhgap25-/- or Arhgap25+/+ hematopoietic cell 319 
populations that express CD45.2. Using these animals, we investigated the extravasation of 320 
leukocytes in cremaster muscle whole mounts after 3 h local stimulation with TNFα. CD45.2-321 
expressing Arhgap25-/- leukocytes were able to transmigrate more efficiently in CD45.1-322 
expressing WT recipients than Arhgap25+/+ cells (Fig. 5A-D). Similar to the results presented 323 
in Fig. 2, we found a threefold increase in leukocyte extravasation in chimeric mice with 324 
Arhgap25-/- hematopoietic cells compared to chimeric mice where WT hematopoietic cells 325 
had been transferred (Fig. 5E). Similar to the results obtained in complete knock-out animals, 326 
mainly neutrophilic granulocytes were responsible for the increase in extravasation followed 327 
by mononuclear cells (marked as “Others”) and eosinophils (Fig. 5F). 328 
These results substantiate that the alteration of leukocyte transendothelial migration 329 
observed in the absence of ARHGAP25 is due to primary changes in the hematopoietic 330 
compartment but not in endothelial or other non-hematopoietic cell compartment.  331 
 332 
Potential mechanism of altered leukocyte function  333 
To examine, whether ARHGAP25 has a regulatory role in the expression of adhesion relevant 334 
molecules and signaling events during neutrophil recruitment, we investigated cell surface 335 
expression and ligand binding ability of receptors and molecules involved in leukocyte-336 
endothelial cell interactions. As shown in Fig. 6A, ARHGAP25 deficiency did not affect the 337 
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expression of β2 integrins (CD18, CD11a and CD11b), L-selectin (CD62L), PSGL-1, 338 
chemokine receptor CXCR2 or CD44. In vitro analysis of adhesion molecule expression after 339 
direct chemotactic migration of neutrophils did not reveal any difference between WT and 340 
Arhgap25-/- cells either (data not shown).  Lack of ARHGAP25 also did not result in any 341 
difference in rmICAM-1 binding to LFA-1 in resting cells. As stimulation of bone marrow-342 
derived neutrophils leads to integrin activation and increased ligand binding (34), we also 343 
investigated binding of rmICAM-1 to neutrophils stimulated with CXCL1 or PMA.  344 
Compared to unstimulated controls, PMA caused a significant increase in rmICAM-1 binding 345 
to LFA-1 on both Arhgap25-/- and wild type neutrophils. However, ARHGAP25-deficiency 346 
did not influence rmICAM-1 binding to stimulated neutrophils. (Fig. 6B). 347 
Our previous study indicated that ARHGAP25 has a regulatory role in neutrophilic 348 
functions through its GAP activity on Rac1 (21). In addition, our in vitro studies demonstrate 349 
that it has a GAP activity on Rac2 as well (data not shown). Therefore, we investigated the 350 
presence of active Rac in bone marrow-derived neutrophils. Interestingly, we observed no 351 
difference in Rac-activity between ARHGAP25-/- and wild type cells in the resting state (Fig. 352 
6C). In contrast, treatment of neutr phils with TNFα resulted in a marked decrease of active 353 
Rac in the presence of ARHGAP25, while the lack of ARHGAP25 completely abolished this 354 
alteration (Fig. 6C).  355 
As Rac is known to be a key regulator of actin-polymerization during leukocyte 356 
migration (35, 36), we measured filamentous actin (F-actin) in Arhgap25-/- and wild type BM 357 
neutrophils. In resting ARHGAP25-deficient cells, increased F-actin was observed compared 358 
to wild type cells (Fig. 6D). Similar difference could be revealed upon stimulation with TNFα 359 
(Fig. 6E). Taken together, we suggest that ARHGAP25 affects actin-polymerization and 360 
depolymerization through its GTPase activating effect on Rac.  361 
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Discussion 362 
The present study provides a detailed characterization of leukocyte recruitment during 363 
inflammation in vivo in ARHGAP25-deficient mice. Alterations have been uncovered for 364 
several steps along the recruitment cascade, indicating a role for the protein in those 365 
processes. Most remarkable is the increase of transmigrating neutrophils observed both in the 366 
inflamed cremaster muscle and the inflamed peritoneal cavity. No striking changes were 367 
found in circulating leukocyte counts between wild type and Arhgap25-/- animals excluding 368 
differences in circulating leukocyte numbers for the observed alterations in leukocyte 369 
recruitment in the absence of ARHGAP25. 370 
Alteration of leukocyte migration may be the result of primary changes in circulating 371 
leukocytes, the endothelial cells, or both. Based on the following observations, we believe that 372 
in case of ARHGAP25-deficient animals, the altered migration is caused by leukocytes: i) 373 
ARHGAP25 was shown to be expressed primarily in hematopoietic cells (21) ii) all the 374 
trafficking alterations observed in living animals could be reproduced with isolated cells 375 
under ex vivo or in vitro condition iii) the difference between the movements of Arhgap25+/+ 376 
and Arhgap25-/- cells was reproduced in bone marrow chimeric animals in vivo, where the 377 
deficiency affected only the hematopoietic but not the endothelial or other peripheral cells. 378 
In control experiments it was verified that ARHGAP25-deficiency had no influence on 379 
the expression of the major leukocyte adhesive proteins and receptors or ligand binding of β2 380 
integrins. On the other hand, stimulation of neutrophils with TNFα resulted in a significant 381 
decrease in measurable GTP-bound Rac which was abolished by absence of ARHGAP25. The 382 
observed increase in the amount of filamentous actin indicates the biological relevance of 383 
enhanced Rac activity (Fig. 6). Deficiency in various RacGEFs was reported to result in 384 
decreased amount of GTP-bound Rac and a decrease in phagocyte migration (16, 37, 38), i.e. 385 
changes opposite to our findings in animals lacking ARHGAP25. We thus ascribe the 386 
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alteration of leukocyte trafficking in ARHGAP25-deficient animals to cytoskeletal 387 
reorganization due to elevation of RacGTP concentration. In human endothelial cells 388 
(HUVECs), TNFα was shown to induce actin-rearrangement through activation of Rho family 389 
small G-proteins (39) and several studies reported the role of TNFα in neutrophil priming and 390 
its involvement in neutrophil effector functions and inside-out signaling (40-43). Our findings 391 
strongly suggest that the leukocyte-specific RacGAP ARHGAP25 is a critical player in 392 
TNFα-induced, Rac-mediated actin reorganization in neutrophils. Two recent reports provide 393 
important information on its physiological role: ARHGAP25 was shown to be required for 394 
actin depolymerization in the course of phagocytosis (21, 44), and it was demonstrated to 395 
undergo significant changes in its phosphorylation pattern and GAP activity upon biological 396 
stimulation (45). TNFα-initiated modulation of the phosphorylation pattern of ARHGAP25 397 
with subsequent alterations of its GAP function may provide the link between the cytokine 398 
effect and the actin cytoskeleton rearrangement.  399 
Taken together, our data indicate that ARHGAP25 is a critical negative regulator of 400 
Rac activity and leukocyte transmigration. This qualifies ARHGAP25 as an interesting drug 401 
target in autoimmune disorders (e.g. rheumatoid arthritis and multiple sclerosis) where 402 
leukocyte recruitment is unwanted. 403 
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Figure legends 551 
 552 
Fig.1. Measurement of leukocyte rolling and crawling in TNFα-stimulated mouse 553 
cremaster muscle venules. Intravital microscopy was conducted to investigate leukocyte 554 
recruitment in the mouse cremaster muscle 2 hours after injection of rmTNFα  (500 ng/mouse 555 
intrascrotally). (A) Leukocyte rolling flux fraction (%) is presented as mean+SEM of 33 556 
vessels from 10 wild type mice and 42 vessels of 12 Arhgap25-/- mice. Mean rolling velocity 557 
of leukocytes (µm/s) (B) was quantified and is shown as bar chart (mean+SEM of 166 558 
Arhgap25+/+ cells and 190 Arhgap25-/- cells), ***: P< .001 compared to Arhgap25+/+. (C) 559 
Number of adherent cells per mm2 vessel wall is given as mean+SEM of 10 (Arhgap25+/+) 560 
and 12 (Arhgap25-/-) separate experiments. (D, E) Leukocyte crawling paths of individual 561 
leukocytes of Arhgap25+/+ (n=163 cells) and Arhgap25-/- (n=154 cells) mice. Direction of 562 
blood flow is indicated by arrows. (F) Accumulated distance of leukocytes. Mean+ SEM of 8 563 
wild type and 7 Arhgap25-/- mice. (G) Mean crawling velocity presented as mean+SEM of 564 
163 Arhgap25+/+ and 154 Arhgap25-/- cells. **: P< .01 compared to Arhgap25+/+. (H) 565 
Euclidean distance determines the length of section between starting and end points of 566 
crawling pathways. Mean+SEM of 8 (Arhgap25+/+) and 7 (Arhgap25-/-) separate experiments 567 
are shown.*: P< .05 compared to Arhgap25+/+.   568 
 569 
Fig. 2. Transmigration of leukocytes under in vivo conditions. (A-D) Representative 570 
images of Giemsa-stained cremaster muscle whole mounts from Arhgap25+/+ and Arhgap25-/- 571 
mice 3 hours after 500 ng intrascrotal rmTNFα injection. Images were captured with a Leica 572 
DMI 6000 B microscope equipped with a 10x/0.30 NA dry objective (Leica) and a Leica DFC 573 
480 camera. ROIs with high leukocyte infiltration (rectangles) are captured with 40x objective 574 
and shown in the right side of the panel (B,D). Bars represent 100 µm. (E) Quantification of 575 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
25 
 
total number of extravasated cells per mm2 microvessel wall surface. (F) Distribution of 576 
extravasated cell types (PMN: neutrophilic granulocytes, Eos: eosinophilic granulocytes, 577 
Others: lymphocytes, macrophages and basophilic granulocytes). Mean+SEM of 3 578 
(Arhgap25+/+) and 7 (Arhgap25-/-) separate experiments.***: P< .001 compared to 579 
Arhgap25+/+. 580 
 581 
Fig. 3. TNFα-induced leukocyte infiltration into the peritoneal cavity.  582 
(A) Hematoxylin and eosin staining of peritoneal tissues 3 hours after intraperitoneal injection 583 
of TNFα. Left side of the panel indicates 2 representative images from Arhgap25+/+ and 2 584 
from Arhgap25-/- mice captured with a 10x objective. ROIs with high leukocyte infiltration 585 
(rectangles) are captured with 40x objective and shown in the right side of the panel. Bars 586 
represents 50 µm. Results shown are representatives of multiple experiments and of multiple 587 
sections and fields. (B) Ly-6G+ cell count measured from peritoneal lavage of Arhgap25+/+ 588 
and Arhgap25-/- mice 3 hours after TNFα administration. Data represent mean+SEM of 6 589 
separate experiments. *: P< .05 compared to Arhgap25+/+. 590 
 591 
Fig. 4. Leukocyte rolling and adhesion under flow conditions and transmigration in a 592 
Transwell assay. (A-C) Ex vivo flow chamber assay. Blood cells of Arhgap25+/+ and 593 
Arhgap25-/- mice were perfused through glass capillaries coated with different cell surface 594 
molecules as indicated in panel B.  Number of rolling (A) and adherent (B) leukocytes per 595 
field of view (FOV) and mean rolling velocity (C) of wild type and Arhgap25-/- animals are 596 
shown. Rolling was assessed in E-selectin coated chambers (A). E: rmE-selectin; I: rmICAM-597 
1; CXCL1: rmKC/CXCL1. Mean+SEM of 4 separate experiments. *: P< .05, **: P< .01, ***: 598 
P<.001 compared to Arhgap25+/+. (D) In vitro transmigration of Arhgap25+/+ and Arhgap25-/- 599 
bone marrow neutrophils pretreated with TNFα toward CXCL12 in an FBS-coated Transwell 600 
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system. Data represent mean+SEM of 4 independent experiments. *: P< .05 compared to 601 
Arhgap25+/+. 602 
 603 
Fig. 5. Leukocyte transmigration in bone marrow chimeric mice carrying Arhgap25-/- or 604 
Arhgap25+/+ hematopoietic cells. (A-D) Representative images of a Giemsa-stained 605 
cremaster muscle whole mount. Microscopic analysis was performed 3 hours after 500 ng 606 
intrascrotal rmTNFα injection. Images were captured with a Leica DMI 6000 B mic oscope 607 
equipped with a 10x/0.30 NA dry objective (Leica) and a Leica DFC 480 camera. ROIs with 608 
high leukocyte infiltration (rectangles) are captured with 40x objective and shown in the right 609 
side of the panel (B,D). Bars represent 100 µm. (E) Quantification of total number of 610 
extravasated cells per mm2 microvessel wall surface. (F) Distribution of transmigrated cell 611 
types (PMN: neutrophilic granulocytes, Eos: eosinophilic granulocytes, Others: lymphocytes, 612 
macrophages, basophilic granulocytes). Mean+SEM of 3 separate experiments. *: P< .05 613 
compared to Arhgap25+/+.  614 
 615 
Fig. 6. Investigation of the potential mechanism of altered migration in Arhgap25-/-cells. 616 
(A) Cell surface expression of molecules relevant in leukocyte-endothelial cell interactions 617 
during recruitment. Mean fluorescence intensity relative to isotype control is presented. 618 
Mean+SEM of 5 separate experiments. Panel B shows binding of ICAM-1 to LFA1. Bone 619 
marrow-derived neutrophils were co-incubated with fluorescently labeled rmICAM-1. Bound 620 
ICAM-1 was detected with flow cytometry. Data are presented as mean fluorescence intensity 621 
ratio relative to unstimulated cells. CCXL1: rmKC/CXCL1, PMA: Phorbol 12-myristate 13-622 
acetate. Mean+SEM of 4 separate experiments is shown. *: P< .05, **: P< .01.  (C) GTP-623 
bound active Rac amount in resting and stimulated bone marrow-derived neutrophils. 624 
Stimulation was carried out with 50 ng/mL TNFα in HBSS+ medium at 37 °C for 10 min. 625 
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After lysis, active Rac was pulled down with PBD-GST-glutathione-sepharose beads. Bar 626 
chart presents densitometric analysis of 6 (unstimulated) and 3 (TNFα-treated) separate 627 
western blot experiments. Under the graph, a representative western blot experiment is shown. 628 
Active and total Rac were decorated with anti-Rac antibody in 1:1000 dilution. (D, E) 629 
Filamentous actin amount of bone marrow-derived neutrophils. Actin was stained with Alexa-630 
488-Phalloidin in 1:500 dilution and measured with flow cytometry. Pane D shows F-actin 631 
content in resting neutrophils from Arhgap25-/- mice as mean fluorescence intensity of 632 
phalloidin relative to Arhgap25+/+. Mean+SEM of 4 separate experiments is present. **: P< 633 
.01 compared to Arhgap25+/+. (E) Changes in relative F-actin content of neutrophils treated 634 
for 5, 10 and 15 minutes with 50 ng/mL TNFα. Mean fluorescence intensity of phalloidin is 635 
expressed relative to unstimulated (0 min) control in each genotype. Mean±SEM of 6 separate 636 
experiments is shown. *: P< .05 compared to Arhgap25+/+. 637 
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Table I. Blood parameters in Arhgap25+/+ and Arhgap25-/- mice.  
Parameter Arhgap25+/+ Arhgap25-/- 
Red blood cells, 106/uL 10.75 ± 0.08 10.69 ± 0.22 
Hematocrit, % 52.78 ± 0.6 53.58 ± 1.57 
MCH, pg 14.83 ± 0.06 14.55 ± 0.03 
MCHC, g/dL 30.23 ± 0.14 29.05 ± 0.27 
Reticulocytes, 103/µL 421.53 ± 32.01 469.35 ± 12.73 
Platelets, 103/µL 807.00 ± 11.88 1017.25 ± 53.07 
WBCs, 103/µL 5.72 ± 1.17 6.11 ± 0.59 
Neutrophils, 103/µL 2.06 ± 0.27 2.32 ± 0.38 
Lymphocytes, 103/µL 3.54 ± 1.20 3.60 ± 0.49 
Monocytes, 103/µL 0.013 ± 0.005 0.085 ± 0.035 
Eosinophils, 103/µL 0.103 ± 0.020 0.093 ± 0.011 
Basophils, 103/µL 0.005 ± 0.003 0.008 ± 0.003 
 
Data presented as mean ± SEM, n= 4 in each genotype. WBCs: white blood cells, MCH: 
mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration. 
